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Participating institutions 
The following Cancer and Leukemia Group B (CALGB)/Alliance for Clinical Trials in Oncology 
(Alliance) institutions participated in this study and contributed at least three patients. For each of 
these institutions, the current or last principal investigator are listed as follows:  
 
The Ohio State University Medical Center, Columbus, OH: Claire F. Verschraegen; Wake Forest 
University School of Medicine, Winston-Salem, NC: Heidi D. Klepin; North Shore University 
Hospital, Manhasset, NY: Jonathan E. Kolitz; Washington University School of Medicine, St. 
Louis, MO: Nancy L. Bartlett; Dana Farber Cancer Institute, Boston, MA: Harold J. Burstein; 
Roswell Park Cancer Institute, Buffalo, NY: Ellis G. Levine; University of Chicago Medical Center, 
Chicago, IL: Hedy L. Kindler; University of Iowa Hospitals, Iowa City, IA: Umar Farooq; Ft. Wayne 
Medical Oncology/Hematology, Ft. Wayne, IN: Sreenivasa Nattam; University of Maryland 
Greenebaum Cancer Center, Baltimore, MD: Heather D. Mannuel; University of Vermont Cancer 
Center, Burlington, VT: Peter A. Kaufman; University of North Carolina, Chapel Hill, NC: Matthew 
I. Milowsky; Mount Sinai School of Medicine, New York, NY: Michael A. Schwartz; Western 
Pennsylvania Hospital, Pittsburgh, PA: Gene G. Finley; University of Massachusetts Medical 
Center, Worcester, MA: William V. Walsh; Dartmouth Medical School, Lebanon, NH: Konstantin 
Dragnev; University of Puerto Rico School of Medicine, San Juan, PR: Eileen I. Pacheco; 
University of California at San Francisco, San Francisco, CA: Charalambos Andreadis; Christiana 
Care Health Services, Inc., Newark, DE: Gregory A. Masters; Eastern Maine Medical Center, 
Bangor, ME: Sarah J. Sinclair; Rhode Island Hospital, Providence, RI: Howard P. Safran; 
University of California San Diego Moores Cancer Center, San Diego, CA: Lyudmila A. 
Bazhenova; University of Alabama at Birmingham, Birmingham, AL: Robert Diasio; Duke 
University Medical Center, Durham, NC: Jeffrey Crawford; Massachusetts General Hospital, 
Boston, MA: David Ryan and Justin Gainor; Virginia Commonwealth University, Richmond, VA: 
Steven R. Grossman and Mary H. Hackney; Weill Medical College of Cornell University, New 
York, NY: Scott T. Tagawa; SUNY Upstate Medical University, Syracuse, NY: Stephen L. 
Graziano. 
 
Patients and treatment 
This study reported on 268 adult patients younger than 60 years with de novo AML who were 
enrolled on CALGB/Alliance study protocols as follows: 8525 (n=8), 8721 (n=1), 9222 (n=18), 
9621 (n=44), 10503 (n=90), 10603 (n=25), and 19808 (n=82). Patients enrolled on CALGB 8525 
were treated with induction chemotherapy consisting of cytarabine and daunorubicin, and were 
randomly assigned to consolidation with or without high-dose (i.e., 3 g/m2) cytarabine (HiDAC) 
followed by maintenance treatment.1 The patient enrolled on CALGB 8721 was assigned to a 
regimen consisting of HiDAC plus asparaginase. Patients enrolled on CALGB 9222 received 
induction chemotherapy consisting of cytarabine and daunorubicin, then consolidation with one 
cycle of HiDAC. Different doses of mitoxantrone were explored, and the consolidation treatment 
was either three cycles of HiDAC monotherapy or one cycle of HiDAC, a cycle of 
cyclophosphamide and etoposide, and one cycle of mitoxantrone and diaziquone, as 
randomized.2 Patients enrolled on CALGB 10503 received induction chemotherapy consisting of 
cytarabine, daunorubicin, and etoposide. After achieving a complete remission, patients received 
HiDAC and etoposide for stem-cell mobilization followed by myeloablative treatment with busulfan 
and etoposide supported by autologous peripheral stem cell transplant. Patients not eligible for 
stem cell transplant received HiDAC. After intensification, patients received the decitabine for 
maintenance.3 Patients enrolled on CALGB 10603 were treated with chemotherapy consisting of 
cytarabine and daunorubicin followed by consolidation with HiDAC with or without midostaurin.4 
Patients enrolled on CALGB 19808 were randomly assigned to receive induction with cytarabine, 
daunorubicin, and etoposide with or without valspodar. After achievement of complete remission, 
patients had intensification with HiDAC and etoposide for stem-cell mobilization followed by 
myeloablative treatment with busulfan and etoposide supported by autologous peripheral blood 
stem cell transplant.5 Patients on CALGB 9621 were treated similarly to those on CALGB 19808.6 
 
All patients gave written informed consent for participation in the studies. All study protocols were 
in accordance with the Declaration of Helsinki and approved by Institutional Review Boards at 
each treatment center.  
 
Definition of clinical endpoints  
Complete remission was defined as no evidence of circulating leukemic blasts or extramedullary 
leukemia for at least 4 weeks, with recovery of morphologically normal bone marrow and blood 
counts (neutrophils ≥1.5 x 109/L and platelets >100 x 109/L, with the exception of CALGB 10503 
and CALGB 10603 which required neutrophils ≥1.0 x 109/L). Disease-free survival was measured 
from the date of complete remission (CR) until the date of relapse or death (from any cause); 
patients alive and in continuous first CR were censored at last follow-up. 
 
Statistical analyses 
Variables considered for model inclusion and evaluated in univariable models were: 10-gene 
relpase signature (as a continuous variable in 10% increments), age (as a continuous variable, in 
10-year increments), sex (male vs female), race (white vs nonwhite), white blood cell count 
[(WBC) as a continuous variable, in 50-unit increments], hemoglobin (as a continuous variable, in 
1-unit increments), platelet count (as a continuous variable, in 50-unit increments), extramedullary 
involvement (present vs absent), ASXL1 (mutated vs wild-type), bi-allelic CEBPA (mutated vs 
wild-type), DNMT3A (mutated vs wild-type), FLT3-ITD (present vs absent), FLT3-TKD (present 
vs absent), GATA2 (mutated vs wild-type), IDH1 (mutated vs wild-type), IDH2 (mutated vs wild-
type), NPM1 (mutated vs wild-type), NRAS (mutated vs wild-type), PTPN11 (mutated vs wild-
type), RAD21 (mutated vs wild-type), RUNX1 (mutated vs wild-type), SMC1A (mutated vs wild-
type), SMC3 (mutated vs wild-type), SRSF2 (mutated vs wild-type), TET2 (mutated vs wild-type), 
WT1 (mutated vs wild-type), ZRSR2 (mutated vs wild-type), ERG (high vs low expression), 
BAALC (high vs low expression), MN1 (high vs low expression). For ERG, BAALC and MN1 
expression, the median value was used as the cut point to divide patients into high and low 
expressers. Variables significant at α=0.2 from the univariable analyses were considered for 
multivariable analyses. For time-to-event endpoints, the proportional hazards assumption was 
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remaining in CR 











Median 46 47 
 
Range 18-59 17-59 
Sex, no. (%) 
  
.71 
Male 57 (55) 86 (52) 
 
Female 47 (45) 78 (48) 
 
Race, no. (%) 
  
1.00 
White 92 (91) 147 (91) 
 
Non-white 9 (9) 15 (9) 
 
CLINICAL CHARACTERISTICS 




Median 9.4 9.3 
 
Range 4.9-25.1 4.8-13.7 
Platelet count (x109/L) 
  
.41 
Median 56 56 
 
Range 8-445 12-433 
WBC count (x109/L) 
  
.17 
Median 25.7 29 
 
Range 0.6-475.0 0.8-308.8 
% Blood blasts 
  
.04 
Median 55 65 
 
Range 0-95 0-97 
% Bone marrow blasts 
  
.03 
Median 65 71 
 
Range 21-93 18-96 
Extramedullary involvement, no. (%) 
  
.09 
Present 35 (35) 39 (24) 
 
Absent 66 (65) 121 (76) 
 
ELN 2017 genetic-risk group, no. (%) 
  
<.001 
Favorable 88 (88) 76 (47) 
 
Intermediate 8 (8) 57 (35) 
 
Adverse 4 (4) 28 (17) 
 
GENE MUTATIONS‡ 
   
ASXL1, no. (%) 
  
.77 
Mutated 4 (4) 9 (5) 
 
Wild-type 100 (96) 155 (95) 
 
CEBPA, no. (%) 
  
.37 
Double Mutated 21 (21) 23 (14) 
 
Wild-type 80 (79) 136 (86) 
 
DNMT3A, no. (%) 
  
.25 
Mutated 37 (36) 70 (43) 
 
R882 Mutated 28 53 
 
Non-R882 Mutated 9 17 
 
Wild-type 67 (64) 94 (57) 
 
FLT3-ITD, no. (%) 
  
<.001 
Present 20 (19) 68 (42) 
 
Absent 84 (81) 94 (58) 
 
FLT3-TKD, no. (%) 
  
.03 
Present 17 (17) 12 (7) 
 
Absent 86 (83) 152 (93) 
 
GATA2, no. (%) 
  
.30 
Mutated 13 (13) 14 (9) 
 
Wild-type 91 (88) 150 (91) 
 
IDH1, no. (%) 
  
.41 
Mutated 8 (8) 18 (11) 
 
Wild-type 96 (92) 146 (89) 
 
IDH2, no. (%) 
  
.68 
Mutated 9 (9) 17 (10) 
 
Wild-type 95 (91) 147 (90) 
 
NPM1, no. (%) 
  
.01 
Mutated 77 (74) 96 (59) 
 
Wild-type 27 (26) 68 (41) 
 
NRAS, no. (%) 
  
.22 
Mutated 19 (18) 21 (13) 
 
Wild-type 85 (82) 143 (87) 
 
PTPN11, no. (%) 
  
.10 
Mutated 15 (14) 13 (8) 
 
Wild-type 89 (86) 151 (92) 
 
RAD21, no. (%) 
  
.74 
Mutated 4 (4) 5 (3) 
 
Wild-type 100 (96) 159 (97) 
 
RUNX1, no. (%)   .02 
Mutated 1 (1) 12 (7)  
Wild-type 103 (99) 152 (93)  
SMC1A, no. (%) 
  
.01 
Mutated 9 (9) 3 (2) 
 
Wild-type 95 (91) 161 (98) 
 
SMC3, no. (%) 
  
.43 
Mutated 8 (8) 8 (5) 
 
Wild-type 96 (92) 156 (95) 
 
SRSF2, no. (%) 
  
.16 
Mutated 1 (1) 8 (5) 
 
Wild-type 102 (99) 155 (95) 
 
TET2, no. (%) 
  
.30 
Mutated 13 (13) 14 (9) 
 
Wild-type 91 (88) 150 (91) 
 
WT1, no. (%) 
  
.004 
Mutated 3 (3) 22 (13) 
 
Wild-type 101 (97) 142 (87) 
 
ZRSR2, no. (%) 
  
.16 
Mutated 1 (1) 8 (5) 
 
Wild-type 103 (99) 156 (95) 
 
    
 
CR, complete remission; CN-AML, cytogenetically normal acute myeloid leukemia; FLT3-ITD, 
internal tandem duplication of the FLT3 gene; FLT3-TKD, FLT3 tyrosine kinase domain mutation 
of the FLT3 gene. 
* For a patient to be considered as not relapsing, their follow-up time had to have been at least 3 
y. 
† P-values for categorical variables are from Fisher’s exact test, P-values for continuous variables 
are from Wilcoxon rank sum test.  



















Supplementary Table 2: Genes differentially expressed between patients who relapsed and 
maintained complete remission (provided as Excel Table) 
 
Supplementary Table 3: Genes differentially expressed between patients with mutations in 
NPM1 and those with wild-type NPM1 (provided as Excel Table) 
 
Supplementary Table 4: Genes differentially expressed between patients with bi-allelic 
CEBPA Mutations and those without (provided as Excel Table) 
 
Supplementary Table 5: Genes differentially expressed between patients with FLT3 
internal tandem duplications and those without (provided as Excel Table) 
 
Supplementary Table 6: Genes putatively differentially expressed between patients who 
relapsed and maintained complete remission after removing genes whose expressions are 
associated with bi-allelic CEBPA mutations, NPM1 mutations or FLT3 internal tandem 






Supplementary Table 7. Predictive ability of 10-gene signature in patients stratified into 
the 2017 European LeukemiaNet genetic-risk groups 
 
 
 Relapsed Maintained CR Total 













Favorable, n (%) 63 (38%) 34 (21%) 54 (33%) 13 (8%) 117 (71%) 47 (29%) 
Intermediate, n (%) 50 (77%) 2 (3%) 6 (9%) 7 (11%) 56 (86%) 9 (14%) 
Adverse, n (%) 28 (88%) 2 (6%) 2 (6%) 0 (0%) 30 (94%) 2 (6%) 
 
CR, complete remission. 
 
  
Supplementary Table 8: Polymorphisms significantly associated with expression of 
genes in the relapse signature (provided as Excel Table) 
